Profusa Amends Convertible Notes With Ascent, Setting $0.338 Floor and VWAP-Based Pricing
Profusa amended two convertible notes with Ascent Partners Fund, setting a $0.338 floor price and VWAP-based conversion terms. The notes, maturing in April 2027, have principal amounts of $555,555.55 and $1,111,111.11. Share reserves are set at 150% of the floor price, and anti-dilution provisions were waived on other notes.
How this was made
The 30-second read
Why it matters
The amendment changes the conversion trigger to the greater of $1.20 or 95% of the five‑day VWAP, with a $0.338 floor, potentially increasing dilution risk.
Market read
A primary 8‑K filing that modifies financing terms for a micro‑cap biotech, likely affecting its share price and investor sentiment.
What to watch
Potential for future equity raise if conversion triggers, providing cash for operations.
Background
Profusa announced amendments to two senior secured convertible notes held by Ascent Partners Fund, adjusting conversion pricing and waiving certain anti‑dilution provisions.
Ticker impact
Profusa filed an 8‑K amendment setting a $0.338 floor price and VWAP‑based conversion terms for its senior secured convertible notes.
likely downward pressure as the floor price may trigger conversions at a discount to market.
Conversion at a $0.338 floor is far below current share price, increasing dilution risk and prompting investors to reassess valuation.
Market effects
May raise concerns for other micro‑cap biotech firms using convertible financing.
Limited to US biotech market.
Minimal global impact.
Counterpoint
If the floor price is seen as a protective measure for noteholders, it could stabilize financing costs.
Key entities
- CompanyProfusa Inc.
Biotech firm issuing the convertible notes.
- InvestorAscent Partners Fund
Holder of the convertible notes.